美股A股
StockGist
Back
S-1/A2026-04-27· grok-4-1-fast-non-reasoning

MOBI · Mobia Medical, Inc. Common Stock

0001628280-26-027560

SEC filing

Summary

Mobia Medical, Inc. is a commercial-stage medical device company offering the FDA-approved Vivistim Paired VNS System, the first clinically validated solution for chronic ischemic stroke survivors with moderate to severe upper extremity impairments, filing an S-1/A for IPO to fund sales expansion and R&D.

Key takeaways

Full analysis

Mobia Medical represents a compelling commercial-stage medtech opportunity in the underserved chronic stroke recovery market. The Vivistim Paired VNS System, FDA PMA-approved in 2021 with breakthrough designation, addresses a critical gap where conventional therapy plateaus after 3-6 months post-stroke. With over 1,000 implants (700 in 2025 alone) and revenue doubling to $32M (81% gross margin), the company demonstrates strong traction since full launch in 2023. The $30B initial TAM targets 1M motivated chronic ischemic stroke survivors, fueled by 800K annual U.S. strokes (87% ischemic) and growing prevalence from improved acute care survival rates. Pivotal VNS-REHAB trial showed 2-3x superior upper limb function gains vs. rehab alone, with durable 1-3 year data, positioning Vivistim as first-mover with robust clinical moat.

Financially, rapid growth masks ongoing losses ($46.5M net loss 2025 vs. $24.6M 2024) and $158M accumulated deficit, with $34M cash runway raising going concern doubts. Single-product dependency, reimbursement gaps (Medicare case-by-case; most commercial plans deny as experimental), and single-source supply amplify risks. IPO proceeds target sales expansion (83-person team) and R&D for next-gen features/indications, critical for scaling to 1,500 stroke centers. 180-day lock-up and $40M converting notes (20-50% discount) signal insider alignment but add dilution.

Leadership brings medtech commercialization expertise; Foust's track record suits scaling. No dual-class structure preserves governance. High materiality as IPO funds path to profitability amid reimbursement catalysts like 2026 CPT APC assignment. Success hinges on payor wins, clinical registries (GRASP), and execution in concentrated hospital channel.